Global Medical Technology Company Partners with Nanotech Firm For Innovative Wound Care Solutions
NWN Speaks to Alltracel Pharmaceuticals Chief Marketing Officer Noel Toolan And Peter Kuzel of Elmarco To Learn More About This Joint VentureAlltracel, a company focused on the woundcare market, has entered into a joint technology and business development agreement with Elmarco, a nanotech company headquartered in the Czech Republic. Noel Toolan tells NWN, “Elmarco has a patent around a process and a machine that can produce large scale electro spinning of nanofibres, known as the Nanospider. We feel Elmarco has made a real breakthrough with this technology and process.”
"We have been working closely with Alltracel over a year on a joint development of new woundcare products," notes Peter Kuzel, Marketing & Sales Director for Elmarco. "The closer partnership in the form of a joint venture was a logical step forward in our cooperation.” Mr. Kuzel also notes the important role of the Technical University of Liberic (TUL) for the research side in the partnership. “The first ideas how to produce nanofibers in large part have been invented there.”
Through this joint venture, Alltracel and Elmarco will look to “commercialize nanotechnology within the wound care business. We will be focused more on the development side of R&D,” notes Mr. Toolan.
The joint venture between the two companies would address all areas of the woundcare market. The market is significant--about $12 billion--according to Mr. Toolan. About 10% of the woundcare market includes what Toolan describes as the classic first aid consumer business. “The majority of the market is comprised of professional woundcare solutions for healthcare institutions including hospitals and nursing homes.”
Currently, Alltracel is in discussions to bring its nano-woundcare solutions to customers in Japan, Europe, and the U.S.